CRIS
Curis, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.35
−1.46%Year over year
Reported trailing growth
- Revenue
- -62.2%
- EBITDA
- +40.7%
- EBIT
- +5.3%
- EPS
- +65.8%
- Free cash flow
- -0.4%
- Operating cash flow
- -0.4%
Forward estimates
Based on analyst estimates
- Revenue
- -69.1%
- EBITDA
- +53.9%
- EPS
- +66.8%
Three-year CAGR
- Revenue
- -2.4%
- EBITDA
- +87.7%
- EBIT
- +26.1%
- Net income
- +82.5%
- EPS
- +91.6%
- Free cash flow
- +31.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026